clinical trial · NCT05284747
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Cardiovascular DiseaseMyocardial InfarctionStrokeCoronary RevascularizationEvolocumabRoutine Lipid Management
brief summary
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).
started
Oct 26, 2022
primary completion
May 29, 2027
completion
May 29, 2027
last updated
Nov 9, 2026
official title
EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol